重组人血管内皮抑制素联合培美曲塞加奈达铂方案治疗晚期肺腺癌的效果观察

Effect observation of Recombinant Human Endostatin combined with Pemetrexed plusing Nadeplatin regimen advanced lung adenocarcinoma

目的观察重组人血管内皮抑制素联合培美曲塞加奈达铂方案治疗晚期肺腺癌的效果。方法选取2015年3月~2017年1月我院接诊的64例晚期肺腺癌患者。将患者按照入院先后顺序分为研究组(32例)和对照组(32例)。对照组应用培美曲塞加奈达铂进行治疗,研究组在对照组基础上应用重组人血管内皮抑制素进行治疗。两个疗程后,比较两组患者的治疗效果和不良反应发生情况。结果研究组患者治疗的总有效率为84.38%,明显高于对照组的56.25%(P<0.05)。两组血红蛋白下降,恶心、呕吐的不良反应发生情况差异有统计学意义(P<0.05);白细胞下降、乏力的不良反应发生情况差异无统计学意义(P>0.05)。结论重组人血管内皮抑制素联合培美曲塞加奈达铂治疗晚期肺腺癌的方法具有高效、不良反应少的优点。

Objective To observe the effect of Recombinant Human Endostatin combined with Pemetrexed plusing Nadeplatin regimen advanced lung adenocarcinoma.Methods From March 2015 to January 2017,64 patients with advanced lung adenocarcinoma treated in our hospital were selected.The patients were divided into the study group （32 cases） and control group （32 cases） according to the admission order.The control group was treated with Pemetrexed combined with Nadeplatin,while the study group was treated with Recombinant Human EndostatinRecombinant Human Endostatin on the basis of the control group.After 2 courses of treatment,the treatment effect and incidence of adverse reactions in patients between the two groups were compared.Results The total effective rate of treatment was 84.38% in the study group,which was significantly higher than that in the control group （56.25%） （P〈0.05）.There was a significant difference in the incidence of adverse reactions of hemoglobin descent,nausea and vomiting between the two groups （P〈0.05）,while there was no significant difference of white blood cell decline,fatigue between the two group （P〉0.05）.Conclusion The method of Recombinant Human Endostatin combined with Pemetrexed plusing Nadeplatin in the treatment of advanced lung adenocarcinoma has the advantages of high efficiency and less adverse reaction.